- AboutOpenClose
- TeamOpenClose
- CareersOpenClose
- Investment FocusOpenClose
- Contract Services & Enabling TechnologiesOpenClose
- Biotech & MedtechOpenClose
- Antimicrobial ResistanceOpenClose
- FoundryOpenClose
- PortfolioOpenClose
- MediaOpenClose
Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced the acquisition of Arranta Bio.
Kineticos takes an immersive stance with their biotech engagements and investments, working closely in a collaborative effort with key leadership…
Kineticos announced today that Frank Lis has joined as President and Chief Executive Officer of Kineticos Ventures, a new subsidiary…
St Andrews-based Eos Advisory has entered into a strategic partnership with Kineticos to co-invest in early-stage Scottish life sciences companies.…
Congratulations to Kineticos’ Founder and CEO, Shailesh Maingi, on joining the Arranta Bio board. Arranta Bio is a human microbiome…
“The Kineticos Disruptor Fund is focused on investing with entrepreneur scientists in disruptive platform technologies in areas of large, unmet…
Kineticos announced today the Kineticos Disruptor Fund, a new life sciences investment fund. The fund will invest in disruptive modalities…